AYTU BIOPHARMA, INC Form DEFA14A: Additional definitive proxy soliciting materials
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2025-10-24: Form DEFA14A; Description FORM DEFA14A; Document aytu20251017_defa14a.htm.
- 2025-03-28: Form DEFA14A; Description FORM DEFA14A; Document aytu20250318_defa14a.htm.
- 2024-05-10: Form DEFA14A; Description FORM DEFA14A; Document aytu20240508c_defa14a.htm.
- 2023-04-07: Form DEFA14A; Description DEFA14A; Document tmb-20230407xdefa14a.htm.
| Filed | Form | Period of report | Description | Document |
|---|---|---|---|---|
| 2025-10-24 | DEFA14A | FORM DEFA14A | aytu20251017_defa14a.htm | |
| 2025-03-28 | DEFA14A | FORM DEFA14A | aytu20250318_defa14a.htm | |
| 2024-05-10 | DEFA14A | FORM DEFA14A | aytu20240508c_defa14a.htm | |
| 2023-04-07 | DEFA14A | DEFA14A | tmb-20230407xdefa14a.htm | |
| 2022-09-27 | DEFA14A | DEFA14A | tmb-20220927xdefa14a.htm | |
| 2022-09-21 | DEFA14A | DEFA14A | tmb-20220921xdefa14a.htm | |
| 2022-04-07 | DEFA14A | DEFA14A | tm2210624d4_defa14a.htm | |
| 2021-05-20 | DEFA14A | FORM DEFA14A | aytu20210520_defa14a.htm | |
| 2021-05-20 | DEFA14A | FORM DEFA14A | aytu20210519_defa14a.htm | |
| 2020-04-09 | DEFA14A | DEFINITIVE ADDITIONAL MATERIALS | ea120542-defa14a_aytubio.htm | |
| 2020-03-30 | DEFA14A | DEFINITIVE ADDITIONAL MATERIALS | ea120160-defa14a_ayutbio.htm | |
| 2019-02-25 | DEFA14A | DEFA14A | aytu_defa14a.htm | |
| 2018-05-14 | DEFA14A | DEFINITIVE ADDITIONAL MATERIALS | defa14a0518_aytubioscience.htm | |
| 2016-10-05 | DEFA14A | DEFA14A | v449780_defa14a.htm | |
| 2016-04-21 | DEFA14A | DEFA14A | v436449_defa14a.htm |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| ARTELO BIOSCIENCES, INC. (ARTL) | United States | $0.023B | |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |